Anika Therapeutics Announces Termination of Worldwide Development and Commercialization Partnership with OrthoNeutrogena
Company Files Pre-Market Approval Applicaton for Cosmetic Tissue Augmentation Product
05-Sep-2005
In related news, Anika also announced that, subsequent to such termination, it has filed a pre-market approval application (PMA) with the U.S. Food and Drug Administration for its CTA product and is currently exploring options for its worldwide commercialization.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Last viewed contents
Plymoth-Plymex GmbH - Bad Honnef, Germany
Go to page
Viron reports positive proof of concept results in arthritis for its VT-346 anti-TNF therapeutic
Go to page
Horizon Discovery Expands Commercial Division with Senior Appointments
Go to page
Prometic Finalizes Major Technology Licencing Agreement in Tunisia
Go to page
pluriSelect GmbH - Leipzig, Germany
Go to page
Faster method to create antibodies for disease research
Go to page
Pharminox signs option to in-license novel telomere signalling targeted agents from Cancer Research Technology
Go to page
To-BBB announces collaboration with Genzyme on brain delivery of biologics for neurodegenerative diseases
Go to page
SRI Instruments Europe GmbH - Bad Honnef, Germany
Go to page
Vellore_A._R._Srinivasan
Go to page
Strand Announces Collaboration with Bio-Rad for its Predictive ADME Suite
Go to page
Macfarlane Burnet Institute for Medical Research and Public Health Limited - Melbourne, Australia
Go to page